Clinical trials: Resolution
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
Onychomycosis, Dermatophytosis
Study Evaluating the Effect of Jublia on Dermatophytomas
This study will examine how Jublia affects dermatophytomas, which are difficult to treat with other therapeutic options.
- Trial name
- NCT03098615
- Testing
- Jublia (Efinaconazole 10% Topical Solution)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Healthy
Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution)
This study aims to demonstrate the bioequivalence between the formulation of 5 mg/mL Tramadol Hydrochloride Oral Solution (08P1902F0) Relative to the reference product Contramal® (100 mg/mL Oral Solution).
- Trial name
- NCT05716763
- Testing
- Tramadol Hydrochloride 5 MG/ML Oral Solution, Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))
- Where
- Jordan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Unither Pharmaceuticals, France
Pulmonary Disease, Chronic Obstructive
Tiotropium Respimat Pharmacokinetic Study in COPD
The purpose of this study is compare the effect of different doses of tiotropium delivered by the HandiHaler and Respimat device on lung function.
- Trial name
- NCT01222533
- Testing
- Tiotropium medium, Tiotropium low, Tiotropium high
- Where
- 11 sites in Belgium, Denmark and 3 more
- Volunteers
- 154 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and ability of an orally inhaled medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered using an eFlow nebulizer in 42 patients with Chronic…
- Trial name
- NCT02948582
- Testing
- Glycopyrrolate Inhalation Solution12.5μg, Glycopyrrolate Inhalation Solution 50μg, Glycopyrrolate Inhalation Solution 100μg
- Volunteers
- 42 people
- Sponsor
- Sunovion Respiratory Development Inc.
Healthy Subjects
A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution
This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution
- Trial name
- NCT02756624
- Testing
- AC-170 0.24%, AC-170 Vehicle
- Where
- United States
- Volunteers
- 516 people
- Sponsor
- Nicox Ophthalmics, Inc.
Healthy
A Study in Healthy Men to Test How BI 1358894 is Taken up and Handled by the Body
The main objective of this trial is to investigate the basic pharmacokinetics of BI 1358894 and its metabolites, total radioactivity, including mass balance, excretion pathways and metabolism following a single oral dose of [14C]…
- Trial name
- NCT04567316
- Testing
- [14C]-radiolabelled BI 1358894, BI 1358894
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Dry Eye
Tobramycin Tear Concentrations
To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.
- Trial name
- NCT00695435
- Testing
- TOBRADEX Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension, TOBREX Ophthalmic Solution
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Ocular Hypertension, Primary Open-Angle Glaucoma
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days.
- Trial name
- NCT01110499
- Testing
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Refractive Error, Myopia
Silicone Hydrogel Contact Lens Clinical and Comfort Benefits With a Multi-Purpose Disinfecting Solution
The purpose of this study was to compare lens comfort on Day 30 for Air Optix® lenses cared for with OPTI-FREE® PureMoist® (OFPM) Multi Purpose Disinfecting Solution (MPDS) compared to Acuvue® Oasys® lenses cared for with…
- Conditions
- Refractive Error, Myopia, Hyperopia, Astigmatism
- Trial name
- NCT01809197
- Testing
- Lotrafilcon B contact lenses, Senofilcon A contact lenses, OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)
- Volunteers
- 387 people
- Sponsor
- Alcon Research
Retinitis Pigmentosa
A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)
The primary objective of the study is to assess the safety and tolerability of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution administered over 6 months versus a vehicle control in patients…
- Trial name
- Lumos (NCT02110225)
- Testing
- rhNGF 60 µg/ml eye drops solution, rhNGF 180 µg/ml eye drops solution
- Where
- 5 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Dompé Farmaceutici S.p.A
Cystic Fibrosis
Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution.
- Trial name
- ELITE (NCT00391976)
- Testing
- Tobramycin solution for inhalation 300 mg
- Volunteers
- 123 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to…
- Trial name
- NCT03573817
- Testing
- Revefenacin, Formoterol
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Mylan Inc.
Chronic Hepatitis B
Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
The purpose of the study was to assess the efficacy and safety of telbivudine at a dose of 20 mg/kg up to a maximum of 600 mg q.d.
- Trial name
- NCT02058108
- Testing
- Telbivudine
- Where
- 29 sites in Bulgaria, Greece and 5 more
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Sickle Cell Disease, Sickle-Cell; Hemoglobin Disease, Thalassemia
Pharmacokinetics of Oral Hydroxyurea Solution
An open label, safety and pharmacokinetic study of oral hydroxyurea solution administered to children from 6 months to 17.99 years (i.e.
- Conditions
- Sickle Cell Disease, Sickle-Cell; Hemoglobin Disease, Thalassemia, Sickle Cell-beta-thalassemia, Sickle Cell Hemoglobin C
- Trial name
- HUPK (NCT03763656)
- Testing
- Oral Hydroxyurea (100 mg/mL) Solution
- Where
- 6 sites in Jamaica, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Nova Laboratories Limited
Asthma
A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.
The primary objective of this study is to determine the efficacy and safety of 4 doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily for four weeks in patients with asthma in comparison to…
- Trial name
- NCT01013753
- Testing
- Olodaterol (BI 1744) high, Olodaterol (BI 1744) medium, Olodaterol (BI 1744) very low
- Where
- 27 sites in Austria, Germany and 4 more
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Peripheral Artery Disease
Optical Imaging Measurement of Intravascular Solution Efficacy Trial
Iodinated contrast is the current gold standard for infrainguinal angiography imaging in patients without renal insufficiency and has also been used with intravascular Optical Coherence Tomography (iOCT) to improve image quality…
- Trial name
- OPTIMISE (NCT01743872)
- Testing
- Contrast Injection, Dextran Injection, CO2 Injection
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Healthy Volunteers
A Study of TAK-881 in Healthy Adults
The main aims of this study are to check for side effects from TAK-881 in healthy adults and to learn how much TAK-881 they can receive without getting side effects from it.
- Trial name
- NCT05059977
- Testing
- TAK-881
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Takeda
Lymphedema, Edema
Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema
To investigate whether addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm.
- Trial name
- Biobridge (NCT02734979)
- Testing
- Biobridge and lymph node transfer
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Conjunctivitis, Bacterial
Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.
Phase III clinical study of non-inferiority, multicenter, double-blind, with comparative group, of parallel groups and randomized. about a ophthalmic topical antibiotic for the treatment of bacterial conjunctivitis.
- Trial name
- PRO-157 (NCT03696342)
- Testing
- Pazufloxacin, Zymar
- Where
- 6 sites in Mexico
- Volunteers
- 46 people
- Sponsor
- Laboratorios Sophia S.A de C.V.